ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model

LOS ANGELES–(BUSINESS WIRE)—- $CDXC #CellularHealth–ChromaDex Corp. (NASDAQ:CDXC) today announced the latest preclinical findings indicating Niagen® (patented nicotinamide riboside) inhibits replication of a form of Coronavirus, the virus that causes COVID-19 infection, in mouse cells. The preclinical study results were published July 8 on scientific publishing website The research conducted jointly at the University of Iowa, Oregon Health & Science University, and the University of Kansas previousl